3 Reasons Rocket Lab Stock Could Double in 2027 -- and 1 Reason It Might Not

Rocket Lab reported record Q2 2026 revenue of $235 million, up 62% year over year, and a record $2.4 billion backlog; it also secured more than $1 billion in additional contracts around the start of Q3. Defense exposure includes more than $1.3 billion in Space Development Agency awards and a $397 million Space Force contract. Neutron could expand the company’s addressable launch market, but its debut remains uncertain: by August, Rocket Lab was targeting delivery to the launchpad in Q4 2026 rather than committing to a first flight.

Analysis

The key underwriting issue is conversion, not demand: backlog and pre-flight commitments do not establish revenue timing, contract economics, or cash returns. Verify funded backlog, milestone schedules, cancellation terms, and segment margins before treating defense awards as a durable earnings floor. Vertical integration may reduce supplier dependence, but it also puts more manufacturing yield, capacity, and working-capital risk on Rocket Lab itself.

Near term, the stock is exposed to schedule language and launch milestones; a pad-delivery target is not equivalent to a first-flight date. Over 1–3 months, any clarification of Neutron test cadence and contract timing could reset expectations. Over 6–18 months, a successful flight would improve credibility for larger national-security missions, while a delay or failure could push opportunities toward established providers such as SpaceX, ULA, and Blue Origin. A successful first flight alone would not prove reliable cadence or attractive economics.

Contrarian point: the existing business may limit downside only if its cash generation can support Neutron development; revenue growth and backlog alone do not prove that cushion. Without valuation, cash-flow, and program-cost data, the article’s implied upside is not a basis for sizing a long position.

Key Decisions for Investors

• Do not chase RKLB solely on backlog or pre-launch commitments. Before adding, verify current valuation, cash and cash-flow trend, Neutron development spend, and how much backlog is funded and scheduled.
• If already long, keep exposure sized for a binary execution event; consider adding only after a disclosed first-flight date and observable test milestones, rather than on aspirational timing.
• Set a thesis review trigger around a further Neutron schedule slip, failed test/flight, or evidence that development spending is outpacing the core business’s ability to fund it. Conversely, a successful flight followed by a credible cadence plan would support reassessing the risk premium.
• Watch for defense contract award and funding details: a rising backlog without timely funded work or improving cash conversion would falsify the view that defense provides a meaningful operating cushion.